REPLIMUNE GROUP, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
REPLIMUNE GROUP, INC. (REPL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 75.30% for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-02-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2023-02-09
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2020-12-31 was 76.30%, a 9.47% increase year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2020-09-30 was 75.30%, a 7.26% increase year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2020-06-30 was 75.00%, a 5.63% increase year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2019-12-31 was 69.70%, a 10.11% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month |
|---|---|---|---|
| 2022-12-31 | 75.30% 10-Q · filed 2023-02-09 | ||
| 2022-09-30 | 75.50% 10-Q · filed 2022-11-03 | ||
| 2021-12-31 | 80.00% 10-Q · filed 2023-02-09 | ||
| 2021-09-30 | 80.20% 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | 76.30% 10-Q · filed 2021-02-04 | 74.80% 10-Q · filed 2022-02-03 | |
| 2020-09-30 | 75.30% 10-Q · filed 2020-11-05 | 74.60% 10-Q · filed 2021-11-04 | |
| 2020-06-30 | 75.00% 10-Q · filed 2020-08-07 | ||
| 2019-12-31 | 69.70% 10-Q · filed 2021-02-04 | 71.00% 10-Q · filed 2021-02-04 | |
| 2019-09-30 | 70.20% 10-Q · filed 2020-11-05 | 71.40% 10-Q · filed 2020-11-05 | |
| 2019-06-30 | 71.00% 10-Q · filed 2020-08-07 | ||
| 2018-12-31 | 63.30% 10-Q · filed 2020-02-13 | 61.70% 10-Q · filed 2020-02-13 | |
| 2018-09-30 | 61.50% 10-Q · filed 2019-11-12 | 61.50% 10-Q · filed 2019-11-12 | |
| 2017-12-31 | 75.00% 10-Q · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |